Hikma and Reddys have way less to gain here than amarin had to lose. 20 company’s could launch a generic and it’ll be a small pie. The situation was ripe for a settlement so not sure what happened
My point is whether their demand was extortionate so that Amarin could not have possibly settled, or whether their demand was doable, but Amarin was cocky/reckless/arrogant/foolish in not settling. That question can only be answered by knowing the facts. It is all dependent on the facts. Neither you or I know the truth because we do not have access to those facts.
It’s unlikely this was the case, R-I market was not built out yet; this completely flies against generic drug scheme. My understanding was Amarin was pissed and NOT going to settle; this was reckless.
It will eventually come out in future lawsuits regarding the above truth, management can’t dodge this question.
Market Data 
Markets 
AI
